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SOCE (STIM1 mediated) and HIF-1 are
important regulators of tumorigenesis;
however, the relationship between them,
as well as the Ca2+ mobilization route in
cancer cells during hypoxia, is unknown.
Li et al. report a regulatory circuit
involving HIF-1 and STIM1 that is required
for SOCE and growth of hypoxic HCCs.
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Hypoxia and intracellular Ca2+ transients are funda-
mental traits of cancer, whereas the route and regu-
lation of Ca2+ mobilization in hypoxic tumorigenesis
are unknown. Here, we show that stromal-interaction
molecule 1 (STIM1), an ER Ca2+ sensor, correlates
with elevated hypoxia-inducible factor-1 alpha (HIF-
1a) in hypoxic hepatocarcinoma cells (HCCs) and is
upregulated during hepatocarcinoma growth. HIF-1
directly controls STIM1 transcription and contributes
to store-operated Ca2+ entry (SOCE). STIM1-medi-
ated SOCE is also required for HIF-1 accumulation
in hypoxic HCCs via activation of Ca2+/calmodulin-
dependent protein kinase II and p300. Administration
of YC-1, a HIF-1 inhibitor, or knockdown of HIF1A
significantly diminishes hypoxia-enhanced STIM1
and suppresses tumorigenesis. Moreover, ectopic
expression of STIM1 or HIF-1a partially reverses
impaired growth of tumors treated with YC-1. These
results suggest a mutual dependency and regulation
of STIM1 and HIF-1 in controlling Ca2+ mobilization
and hypoxic tumor growth and highlight a potential
target for early hypoxia-related intervention.INTRODUCTION
Hypoxia is a common feature within the tumor mass and contrib-
utes to tumor growth (Harris, 2002). The transcription factor
hypoxia-inducible factor-1 (HIF-1), by binding the hypoxia-
responsive elements (HREs), plays a central role in hypoxic
tumorigenesis (Semenza, 2003). Understanding the oxygen-
sensing processes and themechanisms throughwhichHIFs reg-
ulates the cellular response to hypoxia is of great importance for
therapeutically targeting hypoxic tumor growth.
Ca2+-mediated signaling pathways are implicated in tumor
development (Monteith et al., 2007). Stromal interaction mole-388 Cell Reports 12, 388–395, July 21, 2015 ª2015 The Authorscules (STIMs), the single-pass type I membrane proteins, are
ER Ca2+ sensors that control the intracellular Ca2+ concentration
and mediate the activation of store-operated Ca2+ entry (SOCE),
the major route for Ca2+ influx in nonexcitable cells (Vig et al.,
2006; Zhang et al., 2005). Recent studies reported the impor-
tance of STIM1-mediated SOCE in tumor invasion, metastasis,
and angiogenesis (Tsai et al., 2014; Yang et al., 2009). Moreover,
STIM1 upregulation is potentially valuable for diagnosis and
prognosis of cancer (Mayr et al., 2002; van de Vijver et al.,
2002). STIM2 has also been found to contribute to the invasion
and metastasis of cancer (Sobradillo et al., 2014; Stanisz et al.,
2014). Nonetheless, the significance of STIMs in cancer
development under hypoxic conditions remains unclear. In the
present study, we addressed the regulation of STIM1 by HIF-1
and determined Ca2+ mobilization in hypoxic hepatocarcinogen-
esis. We also present the functional significance that STIM1
mediates HIF-1 upregulation and hypoxia-driven tumorigenesis.
Our findings shed light on the role of STIM1 in hypoxic tumor
growth and highlight a potential target for early hypoxia-related
intervention.RESULTS
STIM1 Upregulation Correlates with HIF-1a during
Hypoxic Tumor Growth
We first evaluated whether STIM1 expression correlates with
hepatocarcinoma and HIF-1 by analyzing ten sample sets from
clinical liver cancer patients (as listed in Table S1). To differen-
tiate between the neoplastic and normal regions, tissue sections
were stained with H&E and validated by a pathologist. The
scraped tissues from neoplastic and adjacent area were
collected for HIF-1a and STIM1 staining. HIF-1a and STIM1
expression was significantly higher in the tumor tissues than in
the adjacent tissues (Figures 1A–1C; p < 0.001). Moreover, the
expression of STIM1 and HIF-1a was positively correlated (Fig-
ure 1D; r = 0.8881, p < 0.01).
Prompted by the above-mentioned results, we hypothesized
that STIM1 plays a role in hypoxic hepatocarcinoma growth.
To test this, we established an orthotopic hepatocarcinoma
Figure 1. Elevated STIM1 Correlates with
HIF-1a and Hypoxic Tumor Growth
(A–D) Immunohistochemistry of HIF-1a and STIM1
in the tumor and adjacent tissues of hep-
atocarcinoma patients. (A) The presented images
(4003) were from the same patient. Statistical
analysis of normalized expression of HIF-1a (B)
and STIM1 (C) (integrated optical density [IOD]
against immunoglobulin G [IgG]) in the tumor and
adjacent tissues of ten hepatocarcinoma patients.
***p < 0.001, adjacent versus tumor. (D) Correla-
tion between relative increase fold (against the
adjacent tissues) of HIF-1a and STIM1 in the
above tumor subjects.
(E and F) HepG2 cells (2 3 106 cells/100 ml) were
injected into the left hepatic lobe of CD-1 nude
mice. Tumor size, pO2, and relative expression
of HIF-1a and STIM1 (against b-actin and day 0)
in the tumor tissues were determined as tu-
mor growth. Results are expressed as mean ±
SEM (n = 6).
(G–J) After being cultured in hypoxia (with different
O2 concentrations) for 24 hr, mRNA (G and H) and
protein (I and J) expression of HIF-1a and STIM1 in
HepG2 and Huh7 cells was determined with qPCR
and western blot, respectively. The results were
analyzed and normalized against expression
under normoxia and are expressed as mean ±
SEM (n = 4 independent experiments).
See also Figure S1.xenograft nude mice model using HepG2 hepatocarcinoma cell
(HCC) transplantation. We found that expression levels of both
HIF-1a and STIM1 correlated with tumor size (Figure 1E). The tis-
sue partial pressure of oxygen (pO2) decreased with tumor
growth, whereas the expression of HIF-1a and STIM1 increased
(Figures 1F and S1A), suggesting an invert correlation between
STIM1 expression and pO2.
We next compared the expression of STIM1 and STIM2 in
human HepG2 and Huh7 cells after exposure to different con-
centrations of oxygen for 24 hr in vitro. Consistent with the in vivo
results, hypoxia exposure enhanced HIF-1a and STIM1, rather
than STIM2, expression in HCCs in an O2-concentration-depen-
dent manner (Figures 1G–1J). These results indicate that STIM1
is upregulated in hypoxic tumor growth and correlates with HIF-1
accumulation.Cell Reports 12, 388–HIF-1 Regulates STIM1 Expression
and SOCE under Hypoxia
The above findings led us to speculate
that STIM1 is regulated by HIF-1 under
hypoxic conditions. Employing Vista
software (Frazer et al., 2004), we found
three HIF-1 potential binding sites in
the promoter of STIM1 (Figure 2A;
A1: 3862321–3862340, A2: 3877087–
3877107, and A3: 3877324–3877344 on
the negative strand of chromosome 11).
However, we could not find any potential
HIF-1 binding sites in STIM2 promoter.
Using a chromatin immunoprecipitation(ChIP) assay, we found that HIF-1 bound to the STIM1 promoter
at the above-predicted three sites in hypoxic HepG2 cells (Fig-
ure 2B), whereas HIF-1 could not be co-immunoprecipitated
with STIM1 gene within normoxic HCCs. Among the three
potential binding sites, only A2 contained an HRE sequence
(50-CCGTG-30; see the green arrow in Figure 2A). To identify
which site contributed to the transactivation of STIM1, we trans-
fected the promoter luciferase reporters with respective site
deletion into HepG2 cells and found that only A2 deletion re-
sulted in a reporter significantly less responsive to hypoxia
(Figure 2C). These results demonstrate that the A2 site, which
includes putative HREs, is necessary for the transcriptional
response to hypoxia.
To investigate the relationship between HIF-1 and STIM1, four
small hairpin RNAs (shRNAs) against each of themwere applied.395, July 21, 2015 ª2015 The Authors 389
Figure 2. HIF-1 Transcripts STIM1 and Mediates Hypoxia-Enhanced SOCE in HCCs
(A) Vista predicted binding sites of HIF-1 in the promoters of STIM1. Red arrow, transcription start site; , negative strand.
(B) ChIP assay with HIF-1a or control IgG antibody. The immunoprecipitated DNA was purified from HepG2 cells after exposure to hypoxia (1%O2) for 24 hr, and
the regions from sites A1, A2, and A3 of the human STIM1 promoter as shown in (A) were amplified by PCR.
(C) After transfecting HepG2 cells with luciferase reporters of the STIM1 promoter and the promoter with A1, A2, or A3 deletion, cells were cultured under
normoxia (N) or hypoxia (H; 1% O2) for 24 hr. Luciferase activity of the reporters was determined and normalized with the control group under normoxia.
(D and E) HepG2 cells were transfected with shNC (negative control) or shHIF1A for 48 hr, then cultured in hypoxia (1%O2) for 24 hr. ThemRNA (D) and protein (E)
expression of HIF-1a, STIM1, and b-actin was assayed with qPCR and western blot, respectively. Results of qPCR are expressed as mean ± SEM (n = 4 in-
dependent experiments). *p < 0.05 and **p < 0.01, shNC versus shHIF1A.
(F and G) HepG2 cells were pretreated with PBS (vehicle) or YC-1 (20 mM) for 1 hr and then exposed to hypoxia (1% O2) for 24 hr. mRNA (F) and protein (G)
expression of HIF-1a, STIM1, and b-actin was assessed with qPCR and western blot, respectively. Results of qPCR are expressed as mean ± SEM; n = 4 in-
dependent experiments. **p < 0.01, shNC versus shHIF1A.
(H) Time course of Ca2+ current activation after treatment with IP3 (20 mM) or Iono (1 mM) in normoxia (N) or after 1% O2 (24 hr) treatment (H). The amplitudes are
expressed as mean ± SEM of n = 11 independent cells in each group. *p < 0.05, N versus H.
(I) Ca2+ mobilization in HepG2 cells upon IP3 (20 mM) or Iono (1 mM) challenge under normoxia or after exposure to hypoxia for 24 hr (H). The intracellular Ca2+
concentration is expressed as mean ± SEM of n = 5 independent cells each group. *p < 0.05, N versus H.
(J and K) HepG2 cells were transfected with shNC, shHIF1A, mock, or STIM1 (J) or pretreated with PBS (vehicle) or YC-1 (20 mM) for 1 hr (K) and exposed to
hypoxia (1% O2) for 24 hr. Ca
2+ mobilization in HepG2 cells upon IP3 (20 mM) or Iono (1 mM) challenge was assessed. All kinetic curves are the mean ± SEM of
values observed in 30 cells from five experiments. *p < 0.05, shNC versus shHIF1A; #p < 0.05, shHIF1A versus STIM1 plus shHIF1A.
See also Figure S2.
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Among them, STIM1-shRNA2 and HIF1A-shRNA1 showed the
most potent inhibition on the respective target genes in both
HepG2 and Huh7 cells (Figures S1B and S1C); hence, we re-
named them shSTIM1 and shHIF1A and used them for the func-
tional experiments. To address whether HIF-1 is required for
STIM1 upregulation under hypoxia, we knocked down HIF-1a
in HepG2 cells with shHIF1A and found that hypoxia-enhanced
STIM1 was attenuated at both the mRNA and protein levels
when comparedwith scrambled shRNA (shNC)-transfected cells
(Figures 2D and 2E). Furthermore, the administration of YC-1,
a pharmacological inhibitor of HIF-1 (Yeo et al., 2003), signifi-
cantly reduced STIM1 under hypoxia (Figures 2F and 2G). These
results indicate that HIF-1 contributes to STIM1 production in
hypoxic HCCs.
Since STIM1 functions as an ER Ca2+ sensor for SOCE (Zhang
et al., 2005), its upregulation under hypoxia and its positive cor-
relation with HIF-1 led us to hypothesize that SOCEmaymediate
the Ca2+ transient in hypoxic HCCs. To identify the route of Ca2+
mobilization in hypoxic cancer cells, a whole-cell patch-clamp
technique was performed with HepG2 cells (Figures 2H, S2A,
and S2B). The Ca2+ current in resting hypoxic cells was not
significantly altered (0.2 to 0.3pA/pF) compared with that in
normoxic HCCs. The amplitude of the inward and fast-inacti-
vated current in response to 20 mM of inositol 1,4,5-trisphos-
phate (IP3) or 1 mM ionomycin (Iono) was lower than that in the
hypoxia group (Figure 2H and S2A). Pretreatment with the
SOCE inhibitors 2-aminoethoxydiphenyl borate (2-APB) and
GdCl3 significantly blunted the currents elicited by IP3 in both
normoxic and hypoxic HCCs (Figure S2A), which were consis-
tent with the I–V recordings (Figure S2B).
It is well known that hypoxia can trigger reactive oxygen
species generation, which contributes to the activation of phos-
pholipase C (PLC) (Yadav et al., 2013), a hydrolase of phospha-
tidylinositol 4,5-bisphosphate (PIP2) (Wong et al., 2005). PIP2 is
the precursor of IP3, which is a classical activator of SOCE (Par-
ekh and Putney, 2005; Putney, 2009). Of interest, we found that
the PLC inhibitor U73122 significantly inhibited acute-hypoxia-
enhanced PIP2 hydrolysis and SOCE in both HepG2 and Huh7
cells (Figures S2C and S2D). These results indicate that IP3
may be the activator of hypoxia-enhanced SOCE.
To further assess the route of Ca2+ mobilization in hypoxic
HCCs, a Ca2+-image technique was applied (Figure 2I). In the
absence of extracellular Ca2+, both IP3 and Iono induced gradual
increases in intracellular Ca2+ concentration ([Ca2+]i), which
decayed to pre-stimulation levels in 8–10 min. The increase
in [Ca2+]i did not significantly differ among normoxia- and
hypoxia-treated HepG2 cells, suggesting equal depletion of
Ca2+ stores. Further replenishment of Ca2+ (1.8 mM) to the
extra-cellular solution induced a sustained rise in [Ca2+]i, where
SOCE increased upon hypoxia pre-exposure in a time-depen-
dent manner (Figure 2I). These results suggest that hypoxia
exposure enhancedCa2+mobilization via SOCE, but not through
promoting Ca2+ release from the store.
We next determined the effect of HIF-1 on SOCE in HCCs after
hypoxic treatment for 24 hr. While there was no significant
change in stored Ca2+ release, the extracellular Ca2+ influx was
much lower in the shHIF1A and shSTIM1 groups when
compared to shNC (Figures 2J, S2E, and S2F). Ectopic expres-sion of STIM1 rescued SOCE in shHIF1A-transfected HCCs (Fig-
ure 2J). YC-1 treatment also significantly decreased IP3- and
Iono-initiated SOCE in HepG2 cells after 24-hr hypoxia exposure
(Figure 2K). Together, these results suggest that HIF-1 is
required for hypoxia-enhanced STIM1 and SOCE in HCCs.
STIM1 Feed-Forward Regulates HIF-1 in Hypoxic HCCs
Prompted by above results, we next hypothesized that STIM1
may feed-forward regulate HIF-1 via SOCE. Interestingly, both
Iono and IP3 enhanced the expression of hypoxia-induced
HIF-1a and its downstream target, vascular endothelial growth
factor A (VEGF-A). Knockdown of STIM1 in HCCs significantly
suppressed hypoxia-induced HIF-1a and VEGF-A, which could
not be restored by Iono (Figure 3A). These results suggest
that STIM1-mediated SOCE promotes HIF-1 expression in hyp-
oxic HCCs.
Elevated [Ca2+]i has been identified to activate Ca
2+/calmod-
ulin-dependent protein kinase II (CaMKII) that phosphorylates
p300, thereby increasing HIF-1 transcriptional activity and stabil-
ity under hypoxia (Yuan et al., 2005). To further address the
signaling pathway by which STIM1 regulates HIF-1, Iono and in-
hibitors against SOCE, CaMKII, and p300 were administered to
HepG2 cells under hypoxia for 24 hr. We found that Iono
enhanced the expression of hypoxia-induced HIF-1a and
VEGF-A, which were significantly suppressed by pre-treatment
with the SOCE inhibitor 2-APB, the CaMKII inhibitor KN93
(Yuan et al., 2005), and the p300 inhibitor C646 (Bowers et al.,
2010) (Figures 3B and S3A), suggesting that STIM1-mediated
SOCE upregulates HIF-1a during hypoxia via CaMKII and p300
activation.
The accumulation of HIF-1 in hypoxic HCCs may be attributed
to elevated transcription or impaired degradation. Using shNC-
and shSTIM1-transfected Huh7 cells, we found that STIM1 is
required for an increase in HIF1A mRNA under hypoxia (Fig-
ure 3C). Moreover, the enhanced mRNA expression of HIF1A
was blunted by 2-APB, KN93, andC646 (Figure 3D). On the other
hand, 2-APB, KN93, and C646 also accelerated HIF-1a degra-
dation upon the administration of the translation inhibitor
cycloheximide (CHX) (Figures 3E and S3B). These results sug-
gest that STIM1-mediated SOCE feed-forward regulates HIF-1
in hypoxic HCCs by upregulating its transcription and preventing
degradation.
To further establish the relevance of STIM1 in tumorigenesis
and HIF-1 accumulation, we employed orthotopic xenograft
hepatocarcinoma nude mice. Compared with the shNC group,
knockdown of STIM1 significantly suppressed malignant inva-
sion and expression of HIF-1a and VEGF-A in tumor tissues
(Figures 3F and S3C). These results demonstrate that STIM1
is critical for tumor progression and HIF-1 elevation in
hypoxic HCCs.
STIM1 Mediates Hypoxia-Driven Tumor Growth
In order to investigate whether STIM1 is a HIF-1-downstream,
functionally important target promoting tumor growth, we
compared tumor size and expression of STIM1 and HIF-1a
with a respective shRNA-transfected HepG2 cell xenograft
mice model in vivo. Consistently, HepG2 cells transfected with
shSTIM1 or shHIF1A grew much slower than those transfectedCell Reports 12, 388–395, July 21, 2015 ª2015 The Authors 391
Figure 3. STIM1 Upregulates HIF-1 in Hyp-
oxic HCCs
(A) After shNC- and shSTIM1-transfected HepG2
cells were exposed to hypoxia (1% O2) with Iono
(1 mM) or IP3 (20 mM) for 24 hr, STIM1, HIF-1a,
VEGF-A, and b-actin protein levels were assessed
with western blot. Quantitative results of STIM1
and HIF-1a are expressed asmean ± SEM of three
independent experiments. *p < 0.05 and **p < 0.01
compared with shNC vehicle; yp < 0.05 compared
with shNC + Iono; zp < 0.05 compared with
shNC + IP3.
(B) HepG2 cells were treated with Iono (2 mM),
2-APB (50 mM), KN93 (10 mM), and C646 (30 mM)
and exposed to hypoxia (H; 1% O2) for 24 hr.
Protein levels of STIM1, p-CaMKII, t-CaMKII,
p300, HIF-1a, VEGF-A, and b-actin were assessed
with western blot.
(C) The shNC or shSTIM1 transfected Huh7 cells
were incubated under normoxia (N) or hypoxia
(H, 1% O2) for 24 hr, HIF1A mRNA levels were
assessed with qPCR and expressed as mean ±
SEM of four independent experiments. **p < 0.05,
shNC plus N versus shNC plus H; #p < 0.05, shNC
plus H versus shSTIM1 plus H.
(D) Huh7 cells were exposed to hypoxia (H; 1%O2)
with vehicle (PBS), 2-APB (50 mM), KN93 (10 mM),
and C646 (30 mM) for 24 hr. HIF1A mRNA was
assessed with qPCR and expressed as mean ±
SEM of four independent experiments.
(E) Huh7 cells were exposed under hypoxia with
vehicle (PBS), 2-APB (50 mM), KN93 (10 mM), and
C646 (30 mM) for 24 hr and subsequently treated
with 20 mg/ml cycloheximide (CHX) under hypoxia
for 0–30 min. Cell lysates were used for the
assessment of HIF-1a expression.
(F) shNC- or shSTIM1-transfected HepG2 cells
were transplanted into the left hepatic lobe. H&E
staining and immunohistochemistry (4003) of
STIM1, HIF-1a, and VEGF-A and control IgG in the
tumor tissues at day 15 post-HCC transplantation
were assessed.
See also Figure S3.with shNC in the recipient nude mice (Figure 4A). Knockdown of
HIF1A significantly reduced STIM1 and VEGF-A expression in
tumor cells, while STIM1 deficiency lead to reduced HIF-1a
and VEGF-A (Figures S4A and S4B). The proliferation in
shSTIM1-transfected hypoxic HepG2 cells was also remarkably
reduced when compared with shNC group in vitro (Figure S4C).392 Cell Reports 12, 388–395, July 21, 2015 ª2015 The AuthorsOn the other hand, overexpression of
STIM1 or HIF-1a promoted, while the
HIF-1 inhibitor YC-1 effectively inhibited,
tumor growth and STIM1 expression in
tumor cells in the xenografts. The ectopic
expression of STIM1 or HIF-1a substan-
tially restored tumor growth and expres-
sion of STIM1, HIF-1a, and VEGF-A in
HCCs treated with YC-1 (Figures 4B–4E,
S4D, and S4E). Of note, overexpression
of HIF-1a or STIM1 significantly acceler-
ated pO2 reduction within the tumor tis-sues (Figure 4F). Since both HIF-1 and Ca2+ are key regulators
of oxygen consumption (Degasperi et al., 2006; Semenza,
2003), our results indicate that the accumulation of HIF-1 and
STIM1 aggravate hypoxic conditions in the tumor loci. Together,
these findings support the notion that STIM1 mediates hypoxia-
driven tumorigenesis.
Figure 4. STIM1 Orchestrates HIF-1-Driven
Tumorigenesis
(A) shNC-, shHIF1A-, and shSTIM1-transfected
HepG2 cells (2 3 106 cells/100 ml) were injected
into the left hepatic lobe of CD-1 nude mice, and
the tumor size was examined for tumor growth.
Results were expressed as mean ± SEM; n = 10.
*p < 0.05 and **p < 0.01, shNC versus shSTIM1.
(B–E) After the mock-, STIM1-, or HIF1A-trans-
fected HepG2 cells were transplanted into the left
hepatic lobe, CD-1 nude mice received daily
intraperitoneal injections of vehicle (PBS) or YC-1
(30 mg/g) for 2 weeks. Tumor size was assessed
along with tumor growth (B and C). mRNA
expression of STIM1 (D) and HIF1A (E) in the
fluorescence-activated cell-sorted GFP+-HCCs
from tumor tissues at day 15 post-HCC trans-
plantation. Results were normalized against
b-actin and are expressed as mean ± SEM of
n = 10 mice per group. *p < 0.05, **p < 0.01, and
***p < 0.001 compared to mock plus vehicle; #p <
0.05 compared to mock plus YC-1; yp < 0.05 and
yyp < 0.01 compared to STIM1 plus vehicle; zp <
0.05 and zzp < 0.01 compared to HIF-1 plus
vehicle.
(F) After the mock-, STIM1-, or HIF1A-transfected
HepG2 cells were transplanted into the left hepatic
lobe, pO2 in the tumor tissues was determined as a
function of tumor growth. Results are expressed
as mean ± SEM; n = 10. *p < 0.05 and **p < 0.01
compared to mock.
See also Figure S4.DISCUSSION
STIM1 is a well-known ER Ca2+ sensor that mediates SOCE acti-
vation and promotes tumor invasion and migration (Tsai et al.,
2014; Yang et al., 2009; Zhang et al., 2005). Signaling cascades
initiated or regulated by HIF-1 are essential for the processes of
tumorigenesis (Semenza, 2003). However, there is no general
consensus about the relationship between HIF-1 and STIM1.
Also, the significance of STIM1, as well as the route of Ca2+
mobilization in cancer cells during hypoxia, remain unknown.
In our present study, we identified STIM1 overexpression in
both human and mouse xenograft hepatocarcinoma tissues
that was accompanied by tumor growth and steadily reduced
pO2. Hypoxia-induced HIF-1 promoted STIM1 expression and
SOCE in HCCs by directly binding to the STIM1 promoter.
Knockdown of STIM1 significantly blunted, while overexpression
of STIM1 promoted, tumor growth. Moreover, administration of
YC-1, an agent that inhibited HIF-1, significantly diminished
STIM1 and suppressed xenograft tumorigenesis. Our results
indicate that STIM1 plays a crucial role in hypoxic tumor growth.Cell Reports 12, 388–Hypoxia is an integral part of tumor
growth and has been suggested to regu-
late Ca2+ in tumor cells (Toescu, 2004).
So far, an emerging paradigm for the ac-
tion of hypoxia on Ca2+ signaling was
described. For example, hypoxic pulmo-
nary vasoconstriction and STIM1 expres-sion were greater in distal than in proximal pulmonary arteries
(Weigand et al., 2005). 2-APB, an inhibitor of STIM1 puncta for-
mation and SOCE, was reported to block the induction of HIF-1a
in a concentration-dependent manner (Yuan et al., 2008). Consti-
tutive activity of HIF-1a resulted in accelerated uptake of cyto-
plasmic Ca2+ into intracellular stores and diminished Ca2+
response due to increased SERCA pump expression (Neumann
et al., 2005). The gene downstream of HIF-1, such as VEGF,
induced Ca2+ signaling and IP3 formation (Faehling et al.,
2002). In the present study, we found that the hypoxia-induced
Ca2+ transient was store operated, which is fast inactivated (at
a pA range) and could be inhibited by 2-APB or GdCl3 or by
knockdown of STIM1 in HepG2 cells. The Ca2+ currents elicited
by IP3 or Iono were enhanced after hypoxia exposure. Impor-
tantly, we identified a HIF-1 binding site on the promoter of
STIM1, which contained an HRE. Moreover, HIF-1a reduction
by knockdown or YC-1 administration impaired the rise of
SOCEandSTIM1expression in hypoxicHCCs in vitro and in vivo.
These results elucidate the mechanism by which hypoxia en-
hances SOCE, i.e., via HIF-1 upregulating STIM1.395, July 21, 2015 ª2015 The Authors 393
The impact of Ca2+ on the regulation of HIF-1 is also a
research hotspot in recent years. For instance, 2-APB inhibited
the hyperphosphorylation of p300 and blocked the induction of
HIF-1a in a dose-dependent manner. Hypoxia-evoked HIF-1a
accumulation was blocked by the Ca2+ chelator 1,2-bis-(o-ami-
nophenoxy)-ethane-N,N,N0,N0-tetraacetic acid, tetraacetoxy-
methyl ester (BAPTA-AM) (Yuan et al., 2005). These findings
suggest that SOCE contributes to HIF-1 expression, although
the underlying mechanisms are not revealed. In the present
study, we found that knockdown of STIM1 decreased the
expression of HIF-1 and its proangiogenic downstream target,
VEGF-A, in both hypoxic HCCs in vitro and the tumor tissues
in vivo. In addition, we found that hypoxia- and Iono-enhanced
p300 phosphorylation and HIF-1 accumulation (both mRNA and
protein) could be inhibited by inhibitors of SOCE, CaMKII, and
p300. Since p300 contributes to the stability and translocation
of HIF-1a, and because HIF-1 transcripts several targets,
including NF-kB, which also upregulate HIF-1a (Jiang et al.,
2015), our findings suggest that STIM1-mediated SOCE pro-
motes HIF-1a transcription and prevents HIF-1a degradation.
Of interest, YC-1 significantly reduced STIM1 expression in
HCCs and suppressed tumorigenesis, which could be partially
reversed by STIM1 or HIF-1a overexpression. Ectopic expres-
sion of STIM1 or HIF-1a also accelerated the reduction of pO2
in the tumor tissues in situ. These results suggest that STIM1
orchestrates hypoxic tumorigenesis via feed-forward regulation
of HIF-1a.
In conclusion, this study proposes a regulatory circuit in-
volving STIM1 and HIF-1 under hypoxic conditions that is
required for tumor growth and hypoxia-enhanced Ca2+mobiliza-
tion in HCCs. As the tumor rapidly grows, the oxygen concentra-
tion is significantly lower than in healthy tissues, resulting in the
transactivation of HIF-1 and the transcription of STIM1. The
hypoxia-elevated STIM1 promotes Ca2+ mobilization via medi-
ating SOCE, which contributes to the stabilization of HIF-1a by
activating CaMKII and p300. This regulatory circuit aggravates
the hypoxic microenvironment and accelerates tumor growth.
Together, our findings contribute to a better understanding
of the orchestration of hypoxia and intracellular Ca2+ on tumori-




Paraffin-embedded primary hepatocarcinoma tissues and corresponding
adjacent nontumorous liver samples were obtained from patients at Xinqiao
Hospital (Chongqing, China). Clinicopathological characteristics of hepato-
carcinoma patients were summarized in Table S1. The use of clinical spec-
imens and commercially obtained samples in this study was approved
by the Xinqiao Hospital ethics committee of the Third Military Medical
University.
STIM1 Promoter Luciferase Assay
Plasmid vectors of the STIM1 promoter and the promoter with A1, A2, or A3
deletion were synthesized by Promega (Madison) and transfected into
HepG2 cells as described above. Cells were incubated at 21% O2 (N) or
1% O2 for 24 hr. A luciferase assay was then performed as (Semenza and
Wang, 1992). Relative luciferase activity was expressed as normalized with
the control group under normoxia.394 Cell Reports 12, 388–395, July 21, 2015 ª2015 The AuthorsOrthotopic HepG2 Nude Mice Model
Male CD-1 nude mice (6 weeks old, Charles River Laboratories International)
were housed under specific-pathogen-free conditions. Wild-type HepG2 cells
or cells that stably transfected with lentiviral vectors expressing mock, STIM1,
or shRNAs against blank control, STIM1, or HIF-1A (23 106 cells/100 ml each)
were slowly injected into the left hepatic lobe of CD-1 nude mice. The tumor
volume was calculated according to the formula: tumor volume = (largest
diameter 3 perpendicular height2)/2. After measuring tumor volume, the
tumors were removed from the liver for respective experiments. In some ex-
periments, GFP+ cells were fluorescence-activated cell sorted from the tumor
tissues for specific protein determination. The experimental protocol was
approved by the experimental animal care commission of Huazhong University
of Science and Technology and the Third Military Medical University.
Determination of pO2 in the Liver
Bi-modality magnetic resonance imaging/electron paramagnetic resonance
imaging (MRI/EPRI) was performed in a 300-MHz single-point-imaging scan-
ner to measure pO2 as described previously (Hyodo et al., 2012). Briefly,
Oxo63 was injected into the mice via tail vein catheter. The pO2mapping relied
on the linear relationship between pO2 and line width of the triarylmethyl
(Oxo63). To quantify the line width in a voxel, images with increasing readout
delay were obtained. From the images with successively increasing readout
delay, the line width of Oxo63 was mapped over the tissue region. Finally,
using the line-width map, pO2 was calculated from a calibration curve calcu-
lated in vitro.
Statistical Analysis
Statistical analysis was performed using the statistical program SPSS 19.0 for
windows (SPSS). All data are presented as mean ± SEM and were analyzed by
one-way ANOVA. p values < 0.05 were considered statistically significant.
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